Apollo Hospitals hits record ₹8,948 then fades as Q4 profit jumps 36% to ₹529 crore
Apollo Hospitals touched an all-time high before slipping negative despite strong Q4 results: net profit up 36% YoY to ₹529 crore, revenue up 18% to ₹6,605 crore, EBITDA up 31.5% to ₹1,011 crore at 15.3% margin. The Apollo 24x7 demerger and Keimed merger point to a consumer-facing omnichannel pharmacy and digital health retail play. Target ₹9,350.
What happened
Apollo Hospitals hit a record high before turning negative. Q4 net profit rose 36% to ₹529 crore. Its omnichannel pharmacy 24x7 demerger and Keimed merger
Key facts
- ₹8,948.10 record high
- net profit ₹529 crore up 36% YoY
- revenue ₹6,605 crore up 18% YoY
- EBITDA ₹1,011 crore up 31.5%
- margin 15.3%
- 8,131 beds
- 68% occupancy
- target ₹9,350
Why this matters
The Apollo 24x7 demerger plus Keimed merger reframes the story from hospitals to a consumer-facing digital health retail platform, opening pharmacy-scale M&A and partnership optionality that should be aggressively pursued while momentum is high.
What to watch
- Apollo 24x7 demerger record/effective date and standalone valuation guidance
- Keimed merger regulatory approvals and integration milestones
- Sequential EBITDA margin trend and hospital occupancy/ARPOB metrics
- Pharmacy segment losses narrowing or widening
- FII/DII flow data and any block trades near ₹8,900-9,000
- Analysts likely raise targets citing margin trajectory and omnichannel pharmacy TAM
- Watch for institutional block deals and mutual fund position changes post-results
- Management commentary on demerger timeline and Apollo 24x7 profitability path
- Peer hospital chains (Max, Fortis, Narayana) may see sympathy moves